Item |
Information |
Drug Groups
|
approved |
Description
|
One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms. [PubChem] |
Indication |
For treatment of severe infections caused by susceptible bacteria. |
Pharmacology |
Cefotiam is a third generation beta-lactam cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cefotiam works by inhibiting bacterial cell wall biosynthesis. |
Toxicity |
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. |
Affected Organisms |
• |
Enteric bacteria and other eubacteria |
|
Absorption |
Rapidly absorbed following intramuscular injection. Bioavailability is 60% following intramuscular injection. |
Half Life |
Approximately 1 hour. |
Protein Binding |
40% |
References |
• |
Muller R, Bottger C, Wichmann G: Suitability of cefotiam and cefuroxime axetil for the perioperative short-term prophylaxis in tonsillectomy patients. Arzneimittelforschung. 2003;53(2):126-32.
[Pubmed]
|
• |
Kolben M, Mandoki E, Ulm K, Freitag K: Randomized trial of cefotiam prophylaxis in the prevention of postoperative infectious morbidity after elective cesarean section. Eur J Clin Microbiol Infect Dis. 2001 Jan;20(1):40-2.
[Pubmed]
|
• |
Shimizu S, Chen KR, Miyakawa S: Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses. Dermatology. 1996;192(2):174-6.
[Pubmed]
|
|
External Links |
|